• Evotec posted preliminary H1 2026 revenue of about €300.1 million; adjusted EBITDA came in at about -€42.7 million.
• Q2 revenue in Discovery & Preclinical Development fell 15% year-on-year to about €108.1 million; Just - Evotec Biologics dropped 17% to about €35.4 million.
• H1 revenue in Discovery & Preclinical Development slid 16% year-on-year to about €227.9 million; Just - Evotec Biologics declined 29% to about €72.3 million.
• Liquidity totaled about €465.6 million as of June 30, 2026; D&PD net sales excluding strategic partnerships rose about 28% year-on-year in H1.
• Evotec cut its 2026 revenue outlook to about €570 million-€610 million; it now sees adjusted EBITDA of about -€70 million to -€105 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2365130_en) on July 13, 2026, and is solely responsible for the information contained therein.